Cargando…

1507. Pharmacodynamic Target Attainment of Daptomycin Against Staphylococcus aureus for Treatment of Pediatric Osteomyelitis

BACKGROUND: Daptomycin (DAP) is lipopeptide that frequently is used to treat infections caused by Staphylococcus aureus in adult patients. There are limited data using daptomycin in pediatric patients for the treatment of osteomyelitis caused by S. aureus. This study’s objective is to describe pharm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stimes, Grant, Girotto, Jennifer E, Courter, Joshua D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809531/ http://dx.doi.org/10.1093/ofid/ofz360.1371

Ejemplares similares

973. Pharmacokinetic/Pharmacodynamic Evaluation and Dose Optimization of Daptomycin in Pediatric Patients with Staphylococcus aureus Bacteremia
por: Olney, Katie B, et al.
Publicado: (2023)

117. Adjunctive Daptomycin in the Treatment of staphylococcus Aureus Bacteremia
por: Cheng, Matthew P, et al.
Publicado: (2020)

1539. Dalbavancin, Vancomycin, and Daptomycin Alone and in Combination with Cefazolin Against Vancomycin Intermediate-Resistant (VISA) and Daptomycin Non-Susceptible (DNS) Staphylococcus aureus
por: Abdul-Mutakabbir, Jacinda, et al.
Publicado: (2019)

2531. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dosing Regimens for Patients with Staphylococcus aureus Bacteremia (SAB)
por: Bhavnani, Sujata M, et al.
Publicado: (2023)

1062. Daptomycin/Ceftaroline in Combination vs. Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Fox, Matthew, et al.
Publicado: (2018)

596. Distinct, Segregated Daptomycin-Susceptible and Daptomycin-Nonsusceptible Staphylococcus aureus Populations Associated with Tricuspid-Valve Infective Endocarditis
por: Miller, Christopher R, et al.
Publicado: (2019)

1588. Delafloxacin Activity Against Staphylococcus aureus with Reduced Susceptibility or Resistance to Methicillin, Vancomycin, Daptomycin, or Linezolid
por: Saravolatz, Louis D, et al.
Publicado: (2019)

627. Molecular Epidemiology of Daptomycin-resistant Staphylococcus aureus Causing Bloodstream Infections
por: Gudipati, Smitha, et al.
Publicado: (2019)

Defining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic Approach
por: Garonzik, Samira M., et al.
Publicado: (2016)

Dalbavancin, Vancomycin and Daptomycin Alone and in Combination with Cefazolin against Resistant Phenotypes of Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model
por: Abdul-Mutakabbir, Jacinda C., et al.
Publicado: (2020)

Resolution of Staphylococcus aureus (methicillin-resistant Staphylococcus aureus) osteomyelitis by oral linezolid
por: Gomes, PN, et al.
Publicado: (2003)

613. Suppression of Daptomycin Resistance Development in Staphylococcus aureus Is a Class Effect of β-Lactams and Is Independent of Daptomycin–β Lactam Synergy
por: Miller, Christopher R, et al.
Publicado: (2019)

Effectiveness of Daptomycin in Patients with Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia Despite Vancomycin
por: Kale-Pradhan, Pramodini, et al.
Publicado: (2017)

711. Molecular Epidemiology of Daptomycin Nonsusceptibility in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia
por: Sundaram, Ayesha, et al.
Publicado: (2018)

2452. Treatment and Outcomes of Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Bloodstream Infections
por: Hadid, Hind, et al.
Publicado: (2018)

197. Evaluation of Risk Factors and Outcomes Associated with Daptomycin-nonsusceptible Staphylococcus aureus Bacteremia
por: Hanna, Zachary W, et al.
Publicado: (2023)

Catalase Protects Biofilm of Staphylococcus aureus against Daptomycin Activity
por: El Haj, Cristina, et al.
Publicado: (2021)

LB3. Daptomycin Plus Fosfomycin vs. Daptomycin Monotherapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: A Multicenter, Randomized, Clinical Trial
por: Pujol, Miquel, et al.
Publicado: (2018)

Daptomycin-Nonsusceptible Staphylococcus aureus: The Role of Combination Therapy with Daptomycin and Gentamicin
por: Jiang, Jhih-Hang, et al.
Publicado: (2015)

1507 Impact of Electronic Compliance Monitoring in an Ambulatory Pediatric Orthopedic Clinic
por: Edmonds, Sarah, et al.
Publicado: (2014)

1222. Risk Factors and Outcomes for Daptomycin Nonsusceptible Methicillin-Resistant Staphylococcus aureus Bloodstream Infections
por: Hadid, Hind, et al.
Publicado: (2018)

2321. Epidemiology of Staphylococcus aureus Infections in Patients Admitted to Freestanding Pediatric Hospitals, 2009–2016
por: Spaulding, Alicen B, et al.
Publicado: (2018)

Daptomycin-Induced Severe Hyperkalemia With Normal Creatine Kinase in a Patient With Methicillin-Resistant Staphylococcus aureus Osteomyelitis
por: Sawhney, Kiranpreet K, et al.
Publicado: (2023)

Evolution of Antibiotic Tolerance During Oxacillin, Daptomycin and Dalbavancin Therapy Results in Breakthrough Staphylococcus aureus Bacteremias
por: Berti, Andrew, et al.
Publicado: (2017)

2403. Comparison of Daptomycin Combination Therapy With Ceftaroline or Oxacillin Against Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates Causing Persistent Bacteremia
por: Bouchard, Jeannette, et al.
Publicado: (2018)

1651. Utility of Staphylococcus aureus Nares Screening in Hospitalized Children with Osteomyelitis
por: Sands, Ashley, et al.
Publicado: (2023)

307. Rapid Resistance Development to Three Antistaphylococcal Therapies in Daptomycin-tolerant Staphylococcus aureus Bacteremia
por: Miller, Christopher R, et al.
Publicado: (2020)

Antimicrobial Activity of Dalbavancin Tested against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from United States (US) Medical Centers
por: Sader, Helio S, et al.
Publicado: (2017)

2793. Clinical Outcomes of Combination Therapy with Daptomycin and Ceftaroline for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection
por: Chapin, Ryan W, et al.
Publicado: (2023)

Daptomycin in treatment of Methicillin-resistant Staphylococcus aureus diskitis
por: Parlato, Ciro, et al.
Publicado: (2011)

Antibiotic Combinations with Daptomycin for Treatment of Staphylococcus aureus Infections
por: Nadrah, Kristina, et al.
Publicado: (2011)

Daptomycin susceptibility of methicillin resistant Staphylococcus aureus (MRSA)
por: Kaur, Rajneet, et al.
Publicado: (2012)

In vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Staphylococcus aureus (SA) in the Murine Thigh Infection Model
por: Lepak, Alexander J, et al.
Publicado: (2017)

1643. Pharmacodynamics (PD) of Daptomycin (DAP) in Combination Therapy for Enterococcal Bloodstream Infection (BSI)
por: Avery, Lindsay, et al.
Publicado: (2018)

Hyperbaric Oxygen Therapy is Ineffective as an Adjuvant to Daptomycin with Rifampicin Treatment in a Murine Model of Staphylococcus aureus in Implant-Associated Osteomyelitis
por: Jørgensen, Nis Pedersen, et al.
Publicado: (2017)

Fitness Cost of Daptomycin-Resistant Staphylococcus aureus Obtained from in Vitro Daptomycin Selection Pressure
por: Li, Shuguang, et al.
Publicado: (2017)

276. Comparison of Ceftaroline in Combination with Either Vancomycin or Daptomycin for the Treatment of Methicillin-resistant Staphylococcus aureus Bacteremia
por: Welch, Stephanie N, et al.
Publicado: (2020)

Daptomycin Therapy for Osteomyelitis: A Retrospective Study
por: Gallagher, Jason C, et al.
Publicado: (2012)

2554. What’s Weight Got to Do with It? Prospective Pharmacokinetic/Pharmacodynamic Evaluation of Fixed-Dose Daptomycin
por: Olney, Katie B, et al.
Publicado: (2023)

Successful salvage therapy with Daptomycin for osteomyelitis caused by methicillin-resistant Staphylococcus aureus in a renal transplant recipient with Fabry-Anderson disease
por: Polilli, Ennio, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_495vc9uqpadfe3kh5onviesopu